Drug approved for drug-resistant multiple myeloma and hitherto incurable cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pfizer for use in el rex feoa subcutaneous therapy for patients with Drug-resistant multiple myeloma, an aggressive and hitherto incurable blood cancer.

(Read: Multiple myeloma cancer to double by 2040: Can it be prevented?).

related topics

Elrexfio is indicated for adult patients with multiple myeloma who have relapsed after at least four lines of certain therapies, the drugmaker said in a statement.

The FDA approved the therapy after studies showed “significant responses” in patients treated with it, Pfizer said.

It further indicated that study data showed that patients who had received four or more lines of other prior therapy achieved an overall response rate of 58% with Elrexfio, with an estimated 82% of patients maintaining remission for at least nine months.

How Elrexfi Can Fight Drug-Resistant Multiple Myeloma?

(Also read: Multiple Myeloma: Common Symptoms of the Disease | Catch it Early).

Elrexfio therapy is “ready to use”, Administered subcutaneously, it is a mature antigen of B cells (responsible for producing antigen immunoglobulins, called antibodies) and help fight myeloma cells.

Multiple myeloma is an aggressive and currently incurable blood cancer that develops in the bone marrow.

“With the remarkable response in this patient population with highly refractory disease, we believe Elrexfio has the potential to become a new standard of care for multiple myeloma,” Angela Hwang, chief commercial officer and president of the global biopharmaceutical business, said in a statement. Pfizer.

statement warns The most common side effect of this drug treatment is cytokine release syndromefatigue, injection site reactions, diarrhea, upper respiratory infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and fever.

(Also: “Science Miracle”: Cancer patient cured of tumor through innovative treatment).

Multiple myeloma is the second most common type of blood cancer, with more than 35,000 new cases diagnosed each year in the United States and 176,000 new cases worldwide.


Source link

Leave a Comment